Defense Health Agency, J-7, Continuing Education Program Office

Advanced Chemical, Biological, Radiological, and Nuclear Pharmacy Course

Live Course, August 25-27, 2025, Maryland

Continuing Education (CE)/Continuing Medical Education (CME) Information

This CE/CME activity is accredited by the DHA, J-7, Continuing Education Program Office (CEPO). This activity provides continuing education for physicians, nurses, physician associates/physician assistants, pharmacists, pharmacy technicians. A certificate of attendance is available for other attendees.

Advanced Chemical, Biological, Radiological, and Nuclear Pharmacy Course (7.50 clock hours)
August 25 0800 - 1700 (ET)
August 26 0800 - 1700 (ET)
August 27 0800 - 1630 (ET)

Learning Objectives:

Day 1:

Advanced CBRN Pharmacy Course: Introduction and Toxicological Thinking

1. Describe the context and need for advanced training in medical management of CBRN casualties
2. Apply the CRESS algorithm to identify toxidromes (consciousness, respirations, eyes, secretions, skin)
3. Identify opportunities to treat chemical, biological, radiological, and nuclear (CBRN) casualties through the LADMER (liberation, absorption, distribution, metabolism, elimination, response) approach
4. Recognize useful reference materials for management of CBRN casualties

Advanced Pharmacological Management of Nerve Agent Casualties

1. Describe nerve agent pathophysiology from molecular to patient level
2. Manage nerve agent casualties at the Role 3/4, and intensive care setting
3. Recognize novel and contingency treatments for cholinergic crisis
4. Integrate NATO-Ally formularies to manage nerve agent casualties
5. Prepare for management of multiple simultaneous severe nerve agent casualties

Metabolic Intoxication

1. Describe fundamental principles for identifying and treating a casualty with a metabolic agent intoxication.

Management of Opioids, Anticholenergics, and Miscellaneous Agents

1. Describe the pharmacokinetic properties of naloxone, including its absorption, distribution, metabolism, and elimination.
2. Identify an appropriate antidote for a person poisoned with thallium or arsenic describing its mechanism of action and administration protocol.
3. Select the appropriate pharmacological agent to manage agitation, autonomic activity, and prevent or treat seizures, given a case involving a patient exposed to anticholinergic agents.

Day 2

Shelf-Life Extension Program (SLEP): Ensuring DoD Preparedness for CBRN Response

1. Describe the importance of and initial formation of the Department of Defense (DoD) and Food and Drug Administration's (FDA's) Shelf-Life Extension Program (SLEP)
2. Summarize eligibility requirements for enrolling medications into SLEP
3. Outline chemical treatment considerations for chemical and nerve agent exposures
4. Identify inventory considerations and potential use rates when responding to a chemical attack
5. Compare USCENTCOM's informal SLEP program to the DoD's SLEP program

Pulmonary Agents and Vesicants

1. Identify the clinical effects and rates of recovery of pulmonary agents and vesicants.
2. Summarize the pharmacological therapies used to manage patients exposed to pulmonary agents and vesicants.
3. Given a patient case, select the agent used and appropriate treatment based on exposure history and symptoms.

Day 3 (No CEUs)

Faculty:

Daniel P. Nogee, MD, MHS. Presenter has no relevant financial or non-financial relationship(s) with ineligible companies to disclose.

LTC (ret) Devin A. Wiles, DO, MTM&H, FACMT, FACOEM. Presenter has no relevant financial or non-financial relationship(s) with ineligible companies to disclose.

LTC Ryan C. Costantino, PharmD, MS. Presenter has no relevant financial or non-financial relationship(s) with ineligible companies to disclose.

LTC Gregory Hare, PharmD. Presenter has no relevant financial or non-financial relationship(s) with ineligible companies to disclose.

Masha Yemets, PharmD, DABAT. Presenter has no relevant financial or non-financial relationship(s) with ineligible companies to disclose. Dr. Yemets will discuss off-label use of penicillamine, aminophylline, methylprednisolone.

Disclosures:

DHA J-7 staff, planners, authors, faculty, and content reviewers for this educational activity have no relevant financial or non-financial relationship(s) with ineligible companies to disclose.

Interprofessional Continuing Education (IPCE)

IPCE CREDIT™

In support of improving patient care, DHA, J-7, CEPO is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team, and learners will receive 7.50 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physicians (ACCME)

ACCME ACCREDITED

DHA, J-7, CEPO is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
DHA, J-7, CEPO designated this live course for a maximum of 7.50 *AMA PRA Category 1 Credit*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC)

DHA, J-7, CEPO is accredited by the Joint Accreditation/Interprofessional Continuing Education (IPCE) to provide this Continuing Nursing Education live course for a maximum of 7.50 ANCC contact hours. Nurses should only claim credit commensurate with the extent of their participation in the activity.

Pharmacists (ACPE)

UAN JA4008136-0000-25-082-L01-P

No valid paper/electronic statement of credit will be offered. DHA, J-7, CEPO is accredited by the American Council for Pharmacy Education (ACPE) to provide continuing education for Pharmacists. This knowledge based activity will provide a maximum of 7.50 contact hours of pharmacy continuing education credit. Participant CE records will be electronically communicated to CPE Monitor. There is no cost to participate in this activity.

Pharmacy Technicians (ACPE)

UAN JA4008136-0000-25-082-L01-T

No valid paper/electronic statement of credit will be offered. DHA, J-7, CEPO is accredited by the American Council for Pharmacy Education (ACPE) to provide continuing education for Pharmacy Technicians. This knowledge based activity will provide a maximum of 7.50 contact hours of pharmacy continuing education credit. Participant CE records will be electronically communicated to CPE Monitor. There is no cost to participate in this activity.

Physician Associates/Physician Assistants (AAPA) – Live

DHA, J-7, CEPO has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 7.50 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

ACCME Non-Physician CME Credit

DHA, J-7, CEPO is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education. ACCME Non-Physician CME Credit providers will be provided a certificate of participation for educational activities certified for *AMA PRA Category 1 Credit*™. ACCME Non-Physician CME Credit providers may receive a maximum of 7.50 hours for completing this course.

Other Professionals

All other healthcare professionals completing this CE/CME activity will be issued a Certificate of Attendance indicating participation and the number of hours of CE/CME credit. This may be used for submission to licensing boards for satisfaction of CE/CME requirements.

Commercial Support:

No commercial support was provided for this activity.

Participation Costs:

There is no cost to participate in this activity.

CE/CME Inquiries:

For all CE/CME related inquiries, please contact: dha.ncr.j7.mbx.continuing-education-office@health.mil.

How to Obtain CE/CME Credit:

To receive CE/CME credit, you must complete the program posttest(s) and evaluation(s) before collecting your certificate(s). The posttests and evaluations will be available through 10 September 2025 ET at the following URL: www.dhaj7-cepo.com.